TY - JOUR
T1 - Craniosynostosis in patients with RASopathies
T2 - Accumulating clinical evidence for expanding the phenotype
AU - Ueda, Kimiko
AU - Yaoita, Masako
AU - Niihori, Tetsuya
AU - Aoki, Yoko
AU - Okamoto, Nobuhiko
N1 - Funding Information:
We are grateful to the patients and their families. This study was supported in part by grants from the Japanese Ministry of Health, Labour, and Welfare and from the Practical Research Project for Rare/Intractable Diseases run by the Japan Agency for Medical Research and Development (AMED).
Publisher Copyright:
© 2017 Wiley Periodicals, Inc.
PY - 2017/9
Y1 - 2017/9
N2 - RASopathies are phenotypically overlapping genetic disorders caused by dysregulation of the RAS/mitogen-activated protein kinase (MAPK) signaling pathway. RASopathies include Noonan syndrome, cardio-facio-cutaneous (CFC) syndrome, Costello syndrome, Neurofibromatosis type 1, Legius syndrome, Noonan syndrome with multiple lentigines, Noonan-like syndrome, hereditary gingival fibromatosis, and capillary malformation/arteriovenous malformation syndrome. Recently, six patients with craniosynostosis and Noonan syndrome involving KRAS mutations were described in a review, and a patient with craniosynostosis and Noonan syndrome involving a SHOC2 mutation has also been reported. Here, we describe patients with craniosynostosis and Noonan syndrome due to de novo mutations in PTPN11 and patients with craniosynostosis and CFC syndrome due to de novo mutations in BRAF or KRAS. All of these patients had cranial deformities in addition to the typical phenotypes of CFC syndrome and Noonan syndrome. In RASopathy, patients with cranial deformities, further assessments may be necessary to look for craniosynostosis. Future studies should attempt to elucidate the pathogenic mechanism responsible for craniosynostosis mediated by the RAS/MAPK signaling pathway.
AB - RASopathies are phenotypically overlapping genetic disorders caused by dysregulation of the RAS/mitogen-activated protein kinase (MAPK) signaling pathway. RASopathies include Noonan syndrome, cardio-facio-cutaneous (CFC) syndrome, Costello syndrome, Neurofibromatosis type 1, Legius syndrome, Noonan syndrome with multiple lentigines, Noonan-like syndrome, hereditary gingival fibromatosis, and capillary malformation/arteriovenous malformation syndrome. Recently, six patients with craniosynostosis and Noonan syndrome involving KRAS mutations were described in a review, and a patient with craniosynostosis and Noonan syndrome involving a SHOC2 mutation has also been reported. Here, we describe patients with craniosynostosis and Noonan syndrome due to de novo mutations in PTPN11 and patients with craniosynostosis and CFC syndrome due to de novo mutations in BRAF or KRAS. All of these patients had cranial deformities in addition to the typical phenotypes of CFC syndrome and Noonan syndrome. In RASopathy, patients with cranial deformities, further assessments may be necessary to look for craniosynostosis. Future studies should attempt to elucidate the pathogenic mechanism responsible for craniosynostosis mediated by the RAS/MAPK signaling pathway.
KW - Noonan syndrome
KW - RASopathy
KW - cardio-facio-cutaneous syndrome
KW - craniosynostosis
UR - http://www.scopus.com/inward/record.url?scp=85021365414&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85021365414&partnerID=8YFLogxK
U2 - 10.1002/ajmg.a.38337
DO - 10.1002/ajmg.a.38337
M3 - Article
C2 - 28650561
AN - SCOPUS:85021365414
SN - 1552-4825
VL - 173
SP - 2346
EP - 2352
JO - American Journal of Medical Genetics, Part A
JF - American Journal of Medical Genetics, Part A
IS - 9
ER -